Luu J

No ORCID on file · 3 papers in corpus
preprint 2026
Dienogest interrupts the chemokine signalling axis in endometriotic lesions with resistant signatures providing novel opportunities for personalised treatment.
·doi:10.21203/rs.3.rs-8096027/v1

Abstract Progestins are important first line and adjuvant medications for endometriosis, yet their efficacy varies among patients. Dienogest (DNG), a 4th generation progestin, is one of the most prescribed and successful progestins, althou…

2024
A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.
NAR genomics and bioinformatics ·doi:10.1093/nargab/lqae096

Mucinous ovarian carcinoma (MOC) is a subtype of ovarian cancer that is distinct from all other ovarian cancer subtypes and currently has no targeted therapies. To identify novel therapeutic targets, we developed and applied a new method of…

article 2023
Using a Quantitative High-Throughput Screening Platform to Identify Molecular Targets and Compounds as Repurposing Candidates for Endometriosis
Biomolecules ·doi:10.3390/biom13060965

Endometriosis, defined as the growth of hormonally responsive endometrial-like tissue outside of the uterine cavity, is an estrogen-dependent, chronic, pro-inflammatory disease that affects up to 11.4% of women of reproductive age and gende…